<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p30" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_30{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_30{left:341px;bottom:30px;}
#t3_30{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_30{left:377px;bottom:30px;}
#t5_30{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_30{left:540px;bottom:30px;}
#t7_30{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_30{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_30{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_30{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_30{left:285px;bottom:827px;letter-spacing:-0.26px;}
#tc_30{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_30{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_30{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_30{left:1109px;bottom:28px;letter-spacing:0.29px;}
#tg_30{left:36px;bottom:215px;}
#th_30{left:46px;bottom:209px;letter-spacing:0.13px;}
#ti_30{left:247px;bottom:209px;}
#tj_30{left:36px;bottom:198px;}
#tk_30{left:46px;bottom:192px;letter-spacing:0.13px;word-spacing:-0.06px;}
#tl_30{left:332px;bottom:192px;}
#tm_30{left:36px;bottom:182px;}
#tn_30{left:42px;bottom:176px;letter-spacing:0.13px;}
#to_30{left:257px;bottom:176px;}
#tp_30{left:36px;bottom:165px;}
#tq_30{left:42px;bottom:159px;letter-spacing:0.12px;}
#tr_30{left:45px;bottom:142px;letter-spacing:0.11px;word-spacing:0.02px;}
#ts_30{left:45px;bottom:125px;letter-spacing:0.12px;}
#tt_30{left:330px;bottom:125px;letter-spacing:0.13px;}
#tu_30{left:414px;bottom:125px;}
#tv_30{left:36px;bottom:114px;}
#tw_30{left:46px;bottom:108px;letter-spacing:0.12px;word-spacing:-0.03px;}
#tx_30{left:556px;bottom:108px;}
#ty_30{left:36px;bottom:778px;letter-spacing:0.48px;}
#tz_30{left:36px;bottom:760px;letter-spacing:0.25px;}
#t10_30{left:159px;bottom:778px;letter-spacing:0.32px;word-spacing:-0.31px;}
#t11_30{left:761px;bottom:778px;letter-spacing:0.28px;word-spacing:-0.12px;}
#t12_30{left:1061px;bottom:714px;letter-spacing:-0.1px;}
#t13_30{left:1061px;bottom:696px;letter-spacing:-0.09px;}
#t14_30{left:1061px;bottom:677px;letter-spacing:-0.08px;}
#t15_30{left:1061px;bottom:631px;letter-spacing:-0.09px;}
#t16_30{left:1061px;bottom:612px;letter-spacing:-0.06px;}
#t17_30{left:1061px;bottom:594px;letter-spacing:-0.08px;}
#t18_30{left:1061px;bottom:576px;letter-spacing:-0.09px;}
#t19_30{left:1061px;bottom:557px;letter-spacing:-0.25px;}
#t1a_30{left:36px;bottom:538px;letter-spacing:-0.08px;}
#t1b_30{left:36px;bottom:520px;letter-spacing:-0.12px;}
#t1c_30{left:125px;bottom:514px;letter-spacing:-0.1px;}
#t1d_30{left:321px;bottom:522px;letter-spacing:-0.09px;}
#t1e_30{left:125px;bottom:496px;letter-spacing:-0.09px;}
#t1f_30{left:221px;bottom:503px;}
#t1g_30{left:125px;bottom:720px;letter-spacing:-0.15px;word-spacing:0.05px;}
#t1h_30{left:125px;bottom:701px;letter-spacing:-0.08px;}
#t1i_30{left:125px;bottom:683px;letter-spacing:-0.09px;}
#t1j_30{left:125px;bottom:665px;letter-spacing:-0.13px;word-spacing:0.04px;}
#t1k_30{left:125px;bottom:646px;letter-spacing:-0.09px;}
#t1l_30{left:125px;bottom:628px;letter-spacing:-0.1px;}
#t1m_30{left:253px;bottom:635px;}
#t1n_30{left:125px;bottom:581px;letter-spacing:-0.1px;}
#t1o_30{left:125px;bottom:416px;letter-spacing:-0.1px;}
#t1p_30{left:125px;bottom:362px;letter-spacing:-0.43px;word-spacing:-0.25px;}
#t1q_30{left:125px;bottom:344px;letter-spacing:-0.27px;}
#t1r_30{left:213px;bottom:352px;letter-spacing:-0.27px;}
#t1s_30{left:125px;bottom:326px;letter-spacing:-0.09px;}
#t1t_30{left:125px;bottom:272px;letter-spacing:-0.1px;}
#t1u_30{left:125px;bottom:230px;letter-spacing:-0.08px;}
#t1v_30{left:734px;bottom:507px;letter-spacing:-0.11px;word-spacing:-0.62px;}
#t1w_30{left:922px;bottom:507px;letter-spacing:-0.11px;}
#t1x_30{left:491px;bottom:749px;letter-spacing:-0.09px;}
#t1y_30{left:491px;bottom:730px;letter-spacing:-0.09px;}
#t1z_30{left:491px;bottom:712px;letter-spacing:-0.1px;}
#t20_30{left:491px;bottom:658px;letter-spacing:-0.08px;}
#t21_30{left:491px;bottom:640px;letter-spacing:-0.09px;}
#t22_30{left:557px;bottom:648px;}
#t23_30{left:733px;bottom:730px;letter-spacing:-0.1px;}
#t24_30{left:900px;bottom:738px;letter-spacing:-0.09px;}
#t25_30{left:924px;bottom:730px;letter-spacing:-0.09px;}
#t26_30{left:733px;bottom:679px;letter-spacing:-0.13px;}
#t27_30{left:756px;bottom:686px;}
#t28_30{left:733px;bottom:660px;letter-spacing:-0.06px;}
#t29_30{left:733px;bottom:642px;letter-spacing:-0.1px;word-spacing:-0.32px;}
#t2a_30{left:733px;bottom:624px;letter-spacing:-0.1px;}
#t2b_30{left:821px;bottom:631px;letter-spacing:-0.12px;}
#t2c_30{left:377px;bottom:533px;letter-spacing:-0.09px;}
#t2d_30{left:377px;bottom:514px;letter-spacing:-0.09px;}
#t2e_30{left:377px;bottom:496px;letter-spacing:-0.09px;}
#t2f_30{left:377px;bottom:478px;letter-spacing:-0.11px;}
#t2g_30{left:415px;bottom:485px;}
#t2h_30{left:733px;bottom:342px;letter-spacing:-0.09px;}
#t2i_30{left:989px;bottom:342px;letter-spacing:-0.25px;}
#t2j_30{left:576px;bottom:165px;}
#t2k_30{left:582px;bottom:159px;letter-spacing:0.12px;}
#t2l_30{left:576px;bottom:148px;}
#t2m_30{left:590px;bottom:142px;letter-spacing:0.1px;word-spacing:0.03px;}
#t2n_30{left:585px;bottom:125px;letter-spacing:0.11px;}
#t2o_30{left:638px;bottom:125px;letter-spacing:0.12px;word-spacing:-0.02px;}
#t2p_30{left:1148px;bottom:125px;}
#t2q_30{left:576px;bottom:114px;}
#t2r_30{left:586px;bottom:108px;letter-spacing:0.12px;}
#t2s_30{left:618px;bottom:108px;letter-spacing:0.12px;}
#t2t_30{left:696px;bottom:108px;letter-spacing:0.08px;word-spacing:0.05px;}
#t2u_30{left:376px;bottom:353px;letter-spacing:-0.1px;}
#t2v_30{left:376px;bottom:333px;letter-spacing:-0.09px;}
#t2w_30{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_30{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_30{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_30{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_30{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_30{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_30{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_30{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_30{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s8_30{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s9_30{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.sa_30{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_30{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sc_30{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts30" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg30Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg30" style="-webkit-user-select: none;"><object width="1210" height="935" data="30/30.svg" type="image/svg+xml" id="pdf30" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_30" class="t s0_30">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_30" class="t s1_30">® </span>
<span id="t3_30" class="t s0_30">(NCCN </span>
<span id="t4_30" class="t s1_30">® </span>
<span id="t5_30" class="t s0_30">), All rights reserved. NCCN Guidelines </span>
<span id="t6_30" class="t s1_30">® </span>
<span id="t7_30" class="t s0_30">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_30" class="t s2_30">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_30" class="t s2_30">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_30" class="t s3_30">NCCN Guidelines Version 4.2024 </span>
<span id="tb_30" class="t s3_30">Cancer of the Hypopharynx </span>
<span id="tc_30" class="t s4_30">NCCN Guidelines Index </span>
<span id="td_30" class="t s4_30">Table of Contents </span>
<span id="te_30" class="t s4_30">Discussion </span>
<span id="tf_30" class="t s5_30">HYPO-5 </span>
<span id="tg_30" class="t s6_30">d </span>
<span id="th_30" class="t s7_30">Principles of Imaging (IMG-A)</span><span id="ti_30" class="t s8_30">. </span>
<span id="tj_30" class="t s6_30">h </span>
<span id="tk_30" class="t s7_30">Principles of Radiation Therapy (HYPO-A)</span><span id="tl_30" class="t s8_30">. </span>
<span id="tm_30" class="t s6_30">i </span>
<span id="tn_30" class="t s7_30">Principles of Surgery (SURG-A)</span><span id="to_30" class="t s8_30">. </span>
<span id="tp_30" class="t s6_30">j </span>
<span id="tq_30" class="t s8_30">Adverse pathologic features: extranodal extension, positive margins, close </span>
<span id="tr_30" class="t s8_30">margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, perineural invasion, </span>
<span id="ts_30" class="t s8_30">vascular invasion, and lymphatic invasion </span><span id="tt_30" class="t s7_30">(Discussion)</span><span id="tu_30" class="t s8_30">. </span>
<span id="tv_30" class="t s6_30">k </span>
<span id="tw_30" class="t s7_30">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)</span><span id="tx_30" class="t s8_30">. </span>
<span id="ty_30" class="t s5_30">CLINICAL </span>
<span id="tz_30" class="t s5_30">STAGING </span>
<span id="t10_30" class="t s5_30">TREATMENT OF PRIMARY AND NECK </span><span id="t11_30" class="t s5_30">ADJUVANT TREATMENT </span>
<span id="t12_30" class="t s5_30">Follow-up </span>
<span id="t13_30" class="t s9_30">(FOLL-A, 1 </span>
<span id="t14_30" class="t s9_30">of 2) </span>
<span id="t15_30" class="t s5_30">Recurrent </span>
<span id="t16_30" class="t s5_30">or </span>
<span id="t17_30" class="t s5_30">persistent </span>
<span id="t18_30" class="t s5_30">disease </span>
<span id="t19_30" class="t s9_30">(ADV-3) </span>
<span id="t1a_30" class="t s5_30">T4a, </span>
<span id="t1b_30" class="t s5_30">N0–3 </span>
<span id="t1c_30" class="t s5_30">Induction chemotherapy </span>
<span id="t1d_30" class="t sa_30">k,l </span>
<span id="t1e_30" class="t s5_30">(category 3) </span>
<span id="t1f_30" class="t sa_30">n </span>
<span id="t1g_30" class="t s5_30">Total laryngopharyngectomy </span>
<span id="t1h_30" class="t s5_30">+ ipsilateral or bilateral neck </span>
<span id="t1i_30" class="t s5_30">dissection ± hemi- or total </span>
<span id="t1j_30" class="t s5_30">thyroidectomy, after ipsilateral </span>
<span id="t1k_30" class="t s5_30">or bilateral paratracheal lymph </span>
<span id="t1l_30" class="t s5_30">node dissection </span>
<span id="t1m_30" class="t sa_30">i </span>
<span id="t1n_30" class="t s5_30">or </span>
<span id="t1o_30" class="t s5_30">or </span>
<span id="t1p_30" class="t s5_30">Concurrent systemic </span>
<span id="t1q_30" class="t s5_30">therapy/RT </span>
<span id="t1r_30" class="t sa_30">h,k,m </span>
<span id="t1s_30" class="t s5_30">(category 3) </span>
<span id="t1t_30" class="t s5_30">or </span>
<span id="t1u_30" class="t s5_30">Clinical trial </span>
<span id="t1v_30" class="t s5_30">Response Assessment </span><span id="t1w_30" class="t s9_30">(HYPO-6) </span>
<span id="t1x_30" class="t s5_30">Extranodal </span>
<span id="t1y_30" class="t s5_30">extension and/or </span>
<span id="t1z_30" class="t s5_30">positive margin </span>
<span id="t20_30" class="t s5_30">Other risk </span>
<span id="t21_30" class="t s5_30">features </span>
<span id="t22_30" class="t sa_30">j </span>
<span id="t23_30" class="t s5_30">Systemic therapy/RT </span>
<span id="t24_30" class="t sa_30">h,k </span>
<span id="t25_30" class="t s5_30">(category 1) </span>
<span id="t26_30" class="t s5_30">RT </span>
<span id="t27_30" class="t sa_30">h </span>
<span id="t28_30" class="t s5_30">or </span>
<span id="t29_30" class="t s5_30">Consider systemic </span>
<span id="t2a_30" class="t s5_30">therapy/RT </span>
<span id="t2b_30" class="t sa_30">h,k </span>
<span id="t2c_30" class="t s5_30">CT (with contrast) or </span>
<span id="t2d_30" class="t s5_30">MRI (with and without </span>
<span id="t2e_30" class="t s5_30">contrast) of primary and </span>
<span id="t2f_30" class="t s5_30">neck </span>
<span id="t2g_30" class="t sa_30">d </span>
<span id="t2h_30" class="t s5_30">Recurrent or persistent disease </span><span id="t2i_30" class="t s9_30">(ADV-3) </span>
<span id="t2j_30" class="t s6_30">l </span>
<span id="t2k_30" class="t sb_30">In randomized clinical trials, assessment of response has been done after 2 or 3 cycles. </span>
<span id="t2l_30" class="t s6_30">m </span>
<span id="t2m_30" class="t s8_30">When using concurrent systemic therapy/RT, the preferred agent is cisplatin (category </span>
<span id="t2n_30" class="t s8_30">1). See </span><span id="t2o_30" class="t s7_30">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)</span><span id="t2p_30" class="t s8_30">. </span>
<span id="t2q_30" class="t s6_30">n </span>
<span id="t2r_30" class="t s8_30">See </span><span id="t2s_30" class="t s7_30">Discussion </span><span id="t2t_30" class="t s8_30">on induction chemotherapy. </span>
<span id="t2u_30" class="t s9_30">Post Systemic Therapy/RT or RT </span>
<span id="t2v_30" class="t s9_30">Neck Evaluation (FOLL-A, 2 of 2) </span>
<span id="t2w_30" class="t sc_30">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
